Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Brands

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Hypertension (Dallas, Tex. : 1979)|May 28, 2008
Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood instituteBarry L Carter, Paula T Einhorn, Michael Brands, et al.
Journal of the American Chemical Society|October 27, 2018
Binding Kinetics Survey of the Drugged KinomeVictoria Georgi, Felix Schiele, Benedict-Tilman Berger, et al.
Oncotarget|January 14, 2016
BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patientsTatsuo Sugawara, Pascale Lejeune, Silke Köhr, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|September 23, 2006
Summary of American Heart Association Diet and Lifestyle Recommendations revision 2006Alice H Lichtenstein, Lawrence J Appel, Michael Brands, et al.
Circulation|June 21, 2006
Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee, Alice H Lichtenstein, Lawrence J Appel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2018
Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors <i>In Vitro</i> and <i>In Vivo</i>Gerhard Siemeister, Anne Mengel, Amaury E Fernández-Montalván, et al.
Molecular Cancer Therapeutics|February 3, 2016
Novel Mps1 Kinase Inhibitors with Potent Antitumor ActivityAntje M Wengner, Gerhard Siemeister, Marcus Koppitz, et al.
Molecular Cancer Therapeutics|October 5, 2019
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer ModelsAntje M Wengner, Gerhard Siemeister, Ulrich Lücking, et al.
Chemmedchem|June 17, 2016
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)William J Scott, Martin F Hentemann, R Bruce Rowley, et al.
Chemmedchem|September 30, 2017
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of CancerUlrich Lücking, Arne Scholz, Philip Lienau, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Hypertension (Dallas, Tex. : 1979)|May 28, 2008
Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood instituteBarry L Carter, Paula T Einhorn, Michael Brands, et al.
Journal of the American Chemical Society|October 27, 2018
Binding Kinetics Survey of the Drugged KinomeVictoria Georgi, Felix Schiele, Benedict-Tilman Berger, et al.
Oncotarget|January 14, 2016
BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patientsTatsuo Sugawara, Pascale Lejeune, Silke Köhr, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|September 23, 2006
Summary of American Heart Association Diet and Lifestyle Recommendations revision 2006Alice H Lichtenstein, Lawrence J Appel, Michael Brands, et al.
Circulation|June 21, 2006
Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee, Alice H Lichtenstein, Lawrence J Appel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2018
Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors <i>In Vitro</i> and <i>In Vivo</i>Gerhard Siemeister, Anne Mengel, Amaury E Fernández-Montalván, et al.
Molecular Cancer Therapeutics|February 3, 2016
Novel Mps1 Kinase Inhibitors with Potent Antitumor ActivityAntje M Wengner, Gerhard Siemeister, Marcus Koppitz, et al.
Molecular Cancer Therapeutics|October 5, 2019
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer ModelsAntje M Wengner, Gerhard Siemeister, Ulrich Lücking, et al.
Chemmedchem|June 17, 2016
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)William J Scott, Martin F Hentemann, R Bruce Rowley, et al.
Chemmedchem|September 30, 2017
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of CancerUlrich Lücking, Arne Scholz, Philip Lienau, et al.
Pageof 4